Chimeric Therapeutics is a clinical-stage cell therapy company with a focus on discovering, developing and commercialising novel cell therapies with the most curative potential for patients.
Chimeric Therapeutics
Follow
Get notifications in MyBN when activity occurs.
Company Activity
NEW ROLE: Rebecca McQualter, | 02 Dec 2024 | |
NEW ROLE: Phillip Hains, Chief Financial Officer, Joint Company Secretary, Non Executive Director | 17 Jul 2024 | |
NEW ROLE: Eric Sullivan, Non-Executive Director | 17 Jul 2024 | |
NEWS: Tagged in Chimeric drug declares war on deadly pancreatic cancer | 23 Nov 2023 | |
NEWS: Tagged in Chimeric set to flick switch on clinical leukaemia trial | 20 Nov 2023 | |
NEW ROLE: Jason Litten, | 06 Nov 2023 | |
NEWS: Tagged in Chimeric steps up fight against deadliest brain cancer | 02 Nov 2023 | |
NEWS: Tagged in FDA green-lights Chimeric gastrointestinal cancer drug trials | 31 Oct 2023 | |
NEWS: Tagged in Brain cancer survival hopes lifted in Chimeric trials | 23 Oct 2023 |